ERBB2 and breast carcinoma: And HER2- virus-like particle vaccine showed promise as a new cost-effective modality for prevention and treatment of HER2-positive cancer by reducing spontaneous development of mammary carcinomas by 50%-100% in human HER2 transgenic mice and inhibited the growth of HER2-positive tumors implanted in wild-type mice (85).